A Baker

A Grech

A Thorup

Allan Fohlmann

Anne-Mette Larsen

AS Bellack

B Donohue

BA Cornblatt

BL Burke

C Barrowclough

C Denis

C Gluud

C Henquet

C McRobert

Carsten Hjorthøj

CB Pedersen

Christian Gluud

CR Bowie

D Caspari

D Moher

DH Linszen

DL Larsen

DM Ziedonis

EL Coldham

F Smit

G Haddock

HE Nelson

I Boutron

J Brandt

J Cohen

J Endicott

J Hettema

J RachBeisel

J van Os

J Wilk

JK Wing

JM Lachin

L Arseneault

L Hides

L Petersen

LC Sobell

LL Gluud

Lone Vesterager

LR Greene

M Cleary

M Kamali

M Nordentoft

M Olfson

Merete Nordentoft

Mette TR Madsen

Mikkel C Arendt

NC Stefanis

O Spreen

P Jørgensen

P Munk-Jørgensen

P Vendsborg

R Brooks

RA Stern

RD Weiss

RSE Keefe

S Leucht

S Priebe

S Zammit

SR Kay

SZ Levine

TF Andersen

THM Moore

W Hall

WR Miller

WS Fenton

Trials

English

PubMed

Springer - Publisher Connector

Design paper: The CapOpus trial: A randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis

BACKGROUND: A number of studies indicate a link between cannabis-use and psychosis as well as more severe psychosis in those with existing psychotic disorders. There is currently insufficient evidence to decide the optimal way to treat cannabis abuse among patients with psychosis. OBJECTIVES: The major objective for the CapOpus trial is to evaluate the additional effect on cannabis abuse of a specialized addiction treatment program adding group treatment and motivational interviewing to treatment as usual. DESIGN: The trial is designed as a randomized, parallel-group, observer-blinded clinical trial. Patients are primarily recruited through early-psychosis detection teams, community mental health centers, and assertive community treatment teams. Patients are randomized to one of two treatment arms, both lasting six months: 1) specialized addiction treatment plus treatment as usual or 2) treatment as usual. The specialized addiction treatment is manualized and consists of both individual and group-based motivational interviewing and cognitive behavioral therapy, and incorporates both the family and the case manager of the patient.The primary outcome measure will be changes in amount of cannabis consumption over time. Other outcome measures will be psychosis symptoms, cognitive functioning, quality of life, social functioning, and cost-benefit analyses. TRIAL REGISTRATION: ClinicalTrials.gov NCT00484302

Hjorthøj, Carsten

Fohlmann, Allan

Larsen, Anne-Mette

Madsen, Mette

Vesterager, Lone

Gluud, Christian

Arendt, Mikkel

Nordentoft, Merete

Copenhagen University Research Information System

Design paper: The CapOpus trial: a randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis

Crossref

A Coefficient of Agreement for Nominal Scales. Educational and Psychological Measurement

A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. BMJ

A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry

A: A Compendium of Neuropsychological Test.

Altman DG: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet

Application and Results of the Manchester Short Assessment of Quality of Life (Mansa).

B: CCPP-Copenhagen Community Psychiatric Project. Implementation of community mental health centres in Copenhagen: effects of service utilization, social integration, quality of life and positive and negative symptoms. Soc Psychiatry Psychiatr Epidemiol

Bias in clinical intervention research.

Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry

Cannabis and schizophrenia: results of a follow-up study. Eur Arch Psychiatry Clin Neurosci

Cannabis use and outcome of recent onset psychosis. Eur Psychiatry

Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet

Cannabis use and the risk of later schizophrenia: a review. Addiction

Causal association between cannabis and psychosis: examination of the evidence.

Co-occurring severe mental illness and substance use disorders: a review of recent research. Psychiatr Serv

Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse. 18-month outcomes of a randomised controlled trial.

Early detection and assertive community treatment of young psychotics: the Opus Study Rationale and design of the trial. Soc Psychiatry Psychiatr Epidemiol

Engel RR: Linking the PANSS, BPRS, and CGI: Clinical Implications. Neuropsychopharmacology

Erlenmeyer-Kimling L: The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients. Psychiatry Research

Etschel E, Engel RR: What does the PANSS mean? Schizophrenia Research

Etschel E, Leucht S: Extrapolation between measures of symptom severity and change: An examination of the PANSS and CGI. Schizophrenia Research

EuroQol: the current state of play. Health Policy

for the CONSORT Group: Extending the CONSORT Statement to Randomized Trials of Nonpharmacologic Treatment: Explanation and Elaboration. Ann Intern Med

Health Organization Disability Assessment Schedule (WHODAS

Heinssen RK: Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull

Hjorthøj C: Cannabis use and risk of psychosis in later life. Lancet

Hoag MJ: Comparative efficacy of individual and group psychotherapy: A meta-analytic perspective. Group Dynamics: Theory, Research, and Practice

Integrated treatment of co-occurring mental illness and addiction: clinical intervention, program, and system perspectives.

Is cannabis use psychotogenic? Lancet

L: The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophrenia Research

Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavica

ML: Methodological considerations in the diagnosis of coexisting psychiatric disorders in substance abusers.

Motivational Interviewing. Behav Psychother

O'Callaghan E: Psychopharmacology: insight and comorbid substance misuse and medication compliance among patients with schizophrenia. Psychiatr Serv

O'Connell A: Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test. Cortex

OJ: Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction

OJ: Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ

OJ: The environment and schizophrenia: the role of cannabis use. Schizophr Bull

Opsøgende psykoseteam: Assertive Community Treatment Copenhagen, Institut for sundhedsvæsen;

PB: The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull

PB: The Danish Psychiatric Central Register. Dan Med Bull

PB: The Danish psychiatric register as a tool in epidemiology. Acta Psychiatr Scand Suppl

PD: Administration and interpretation of the Trail Making Test. Nat Protocols

PJ: Predicting Medication Noncompliance After Hospital Discharge Among Patients With Schizophrenia. Psychiatr Serv

Psychometric support for contemporaneous and retrospective youth and parent reports of adolescent marijuana use frequency in an adolescent outpatient treatment population. Addictive Behaviors

Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev

Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. Cochrane Database Syst Rev

Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study.

Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders.

Research in Group Psychotherapy for Substance Abuse: Fiction, Fact, and Future.

Rollnick S: Motivational Interviewing: Preparing People for Change 2nd edition.

Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ

Sobell MB: Timeline Follow-Back: A Technique for Assessing Self-Reported Alcohol Consumption.

Statistical Considerations in the Intent-to-Treat Principle. Controlled Clinical Trials

Substance abuse and the management of medication nonadherence in schizophrenia.

TD: Assessment of client/patient satisfaction: Development of a general scale. Evaluation and Program Planning

TE: Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ

The culture of designing hepato-biliary randomised trials.

The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull

The efficacy of motivational interviewing: a meta-analysis of controlled clinical trials.

The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry

The Hopkins verbal learning test : development of a new memory test with six equivalent forms. Clin Neuropsychol

The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull

Verdoux H: Cannabis use and psychosis: a longitudinal population-based study.

VJ: Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: Randomised controlled trial.

VJ: Comparisons between psychosis samples with different patterns of substance use recruited for clinical and epidemiological studies. Psychiatry Res

White T: Neuropsychological Assessment Battery Lutz, Florida, Psychological Assessment Resources, Inc.;

WHO: International Classification of Diseases (ICD).

WR: Motivational interviewing. Annual Review of Clinical Psychology

Young males have a higher risk of developing schizophrenia: a Danish register study. Psychol Med

file:///data/core-remote/dit/data/Springer-OA/pdf/7e7/aHR0cDovL2xpbmsuc3ByaW5nZXIuY29tLzEwLjExODYvMTc0NS02MjE1LTktNDIucGRm.pdf

Design paper: The CapOpus trial: A randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis

Abstract

Similar works

Full text

Available Versions

Springer - Publisher Connector

Copenhagen University Research Information System

Crossref

Springer - Publisher Connector